Clinical Study Results
Research sponsor: AstraZeneca
Drug studied: Dapagliflozin
Short study title: A study to learn how dapagliflozin affects blood sugar
levels in people with type 2 diabetes who already have
damaged kidneys
Thank you!
Thank you for taking part in the clinical study for the study drug dapagliflozin.
You and all of the participants helped researchers learn more about how
dapagliflozin affects the blood sugar levels in people with type 2 diabetes who
already have damaged kidneys.
AstraZeneca sponsored this study and thinks it is important to share the results
of this study with you and the public. An independent non-profit organization
called CISCRP and a medical writing organization called Synchrogenix helped
prepare this summary of the study results for you. We hope it helps you
understand and feel proud of your important role in medical research.
If you participated in this study and have questions about the results, please
speak with the doctor or staff at your study site.
What is happening with this study now?
The participants were in this study for up to about 33 weeks. But, the entire
study took about 2 and a half years to finish.
This study started in June 2015 and ended in November 2017. This study
included 321 participants in Bulgaria, Canada, the Czech Republic, Italy,
Poland, Spain, Sweden, and the United States.
The sponsor reviewed the data collected when this study ended and created
a report of the results. This is a summary of that report.
1